Cortes, Javier <br/><br/>
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jan 2009 
 - 307-14 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-08-1113  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Genes, erbB-2<br/>Heart Diseases--chemically induced<br/>Humans<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Paclitaxel--administration & dosage<br/>Trastuzumab<br/>Up-Regulation